Type 2 diabetes mellitus with chronic kidney disease
Conditions
Interventions
Experimental group:Huangkui capsules
Control group:Huangkui capsules placebo
Sponsors
Drum Tower Hospital Affiliated to Nanjing University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Meet the diagnostic criteria for type 2 diabetes mellitus with a disease duration of more than 6 months; 2) 100=UACR=2000 mg/g 3)e-GFR=30 ml·min-1·1.73m-2 4) Age 18~75 years old (including 18 years old and 75 years old) gender is not limited; 5) The blood pressure is effectively controlled at =140/90mmHg; 6) Glycosylated hemoglobin =9%; 7) treatment with ARB for = 4 weeks without causing unacceptable side effects; 8) Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Serum potassium >5.0mmol/L; 2) Blood pressure3×ULN); 6) Those with malignant tumors or malignant diseases that affect the overall prognosis; 7) Patients with primary adrenal insufficiency (Addison's disease); 8) Patients who are allergic to finerenone Huangkui capsule components or any excipients; 9) patients with rare hereditary galactose intolerance lactase deficiency or glucose-galactose malabsorption; 10) Clinically confirmed diagnosis of chronic HFrEF with persistent symptoms at the lead-in visit (NYHA class II-IV; MRA's Category 1A Recommendations); 11) Those who were hospitalized due to stroke transient isch
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine albumin/creatinine; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of abnormal serum potassium;Tumor necrosis factor (TNF-a);Glomerular filtration rate;Transforming Growth Factor (TGF-ß1);Hypersensitive C-reactive protein (hs-CRP); | — |
Countries
China
Contacts
Public ContactZhu Dalong
Nanjing Gulou Hospital
Outcome results
None listed